Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Glaxo Group Limited

Jon Loren Collins

Timothy Mark Willson

Jeffrey Alan Oplinger

Eric Steven Furfine

Barry George Shearer

Edward Patrick Garvey

Sharon Davis Boggs

Yulin Wu

Christopher P Holmes

Robert Anthony Mook

Istvan Kaldor

David Norman Deaton

Milana Dezube

Grady Evan Boswell

Matthew J Sharp

Eugene Lee Stewart

Christopher Joseph Aquino

Patrick Reed Maloney

James Martin Lenhard

Marcus Brackeen

Brad Richard Henke

Adam Michael Fivush

Derek James Parks

John Mark O'Callaghan

Jeffrey Edmond Cobb

Greg Alan Erickson

Stephen M Hyatt

The invention relates to methods for the treatment or prevention of an LXR mediated disease or condition, including cardiovascular disease and atherosclerosis, novel compounds of formula (I) for use in such methods and pharmaceutical compositions comprising compounds for use in such methods. 

Purine derivatives as liver X receptor agonists

The invention relates to a compound of formula (I): wherein all variables are as defined herein and to pharmaceutical compositions, methods of using, and processes for preparing the same.

Farnesoid X receptor agonists

The present invention relates, in general, to nuclear receptors and, in particular, to the Constitutive Androstane Receptor (CAR; NR 1I3) and to a method of identifying ligands therefor.

Constitutive androstane receptor

The present invention discloses novel PPAR gamma ligands of Formula (I) and pharmaceutically acceptable salts and solvates thereof. The present invention also discloses a method for treating osteoporosis by administration of a PPAR gamma antagonist.

Thiazole derivatives as PPAR gamma ligands

The present invention discloses compounds of formula (I), and tautomeric forms, pharmaceutically acceptable salts, or solvates thereof. Preferably, the compounds of the invention are dual activators of hPPAR&ggr; and hPPAR{acute over (&agr;)}.

Substituted oxazoles and thiazoles derivatives as hPPAR&ggr; and hPPAR&agr; activators

A class of acetamidine derivatives of general formula (I)

Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C,alkyl, C,alkoxy, C,fluoroalkoxy, nitrile, or &mdash;NR,R,where R,and R,are independently hydrogen or C,alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C,alkylene; (v) &mdash;MC,alkylene or C,alkyleneMC,alkylene, wherein M is O, S, or &mdash;NR,wherein R,represents hydrogen or C,alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C,alkyl; and (vii) Het-C,alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C,alkylene; R,represents hydrogen or C,alkyl; Z is selected from the group consisting of: (viii) &mdash;(C,alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) &mdash;NR,R,, wherein R,represents hydrogen or C,alkyl, and R,represents &mdash;Y&mdash;(C&boxH;O)&mdash;T&mdash;R,, or &mdash;Y&mdash;(CH(OH))&mdash;T&mdash;R,.

Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

Acetamidine derivatives and their use as inhibitors for the nitric oxide

Growing community of inventors

Durham, NC, United States of America

Jon Loren Collins